Veraxa Biotech AG - Post de-SPAC
VRXAW- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002079109
In the last 90 days, Veraxa Biotech AG - Post de-SPAC insiders filed 4 open-market purchases and 0 sales; 27 institutions reported holding it in 13F filings for Q2 2026, worth $992.5K in total; no superinvestor holds it.
Other share classesVRXA
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 14, 2026, 1:18 AM ET
No financial statements
Veraxa Biotech AG - Post de-SPAC has no financial statements on Livermore. They come from the XBRL data in 10-K, 10-Q, 20-F and 40-F filings, so ETFs, funds and companies that don't file these reports have none.